Acinetobacter Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Acinetobacter Infections – Pipeline Review, H2 2017’, provides an overview of the Acinetobacter Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections

The report reviews pipeline therapeutics for Acinetobacter Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acinetobacter Infections therapeutics and enlists all their major and minor projects

The report assesses Acinetobacter Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acinetobacter Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

Acies Bio doo

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

Atterx Biotherapeutics Inc

AvidBiotics Corp

Emergent BioSolutions Inc

Entasis Therapeutics Inc

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

FOB Synthesis Inc

Hsiri Therapeutics LLC

LegoChem Biosciences Inc

Melinta Therapeutics Inc

Nosopharm SAS

Novabiotics Ltd

Peptilogics Inc

Pfizer Inc

Redx Pharma Plc

Sarepta Therapeutics Inc

Sealife PHARMA GMBH

Shionogi & Co Ltd

Techulon Inc

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Xellia Pharmaceuticals ApS

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Acinetobacter Infections - Overview 8

Acinetobacter Infections - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Acinetobacter Infections - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Acinetobacter Infections - Companies Involved in Therapeutics Development 26

Achaogen Inc 26

Acies Bio doo 26

Adenium Biotech ApS 26

Aridis Pharmaceuticals LLC 27

Atterx Biotherapeutics Inc 27

AvidBiotics Corp 28

Emergent BioSolutions Inc 28

Entasis Therapeutics Inc 28

Evaxion Biotech ApS 29

F. Hoffmann-La Roche Ltd 29

FOB Synthesis Inc 30

Hsiri Therapeutics LLC 30

LegoChem Biosciences Inc 31

Melinta Therapeutics Inc 31

Nosopharm SAS 31

Novabiotics Ltd 32

Peptilogics Inc 32

Pfizer Inc 32

Redx Pharma Plc 33

Sarepta Therapeutics Inc 33

Sealife PHARMA GMBH 34

Shionogi & Co Ltd 34

Techulon Inc 35

Tetraphase Pharmaceuticals Inc 35

Vaxdyn SL 36

Xellia Pharmaceuticals ApS 36

Acinetobacter Infections - Drug Profiles 37

A-3APO - Drug Profile 37

AA-139 - Drug Profile 39

AB-877 - Drug Profile 40

Acinetobacter vaccine - Drug Profile 41

Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 42

Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 43

AR-401 - Drug Profile 44

AvR-2V10 - Drug Profile 45

CA-824 - Drug Profile 47

cefiderocol - Drug Profile 48

CSA-13 - Drug Profile 53

EBX-004 - Drug Profile 55

ETX-2514 + sulbactam sodium - Drug Profile 56

EV-035 - Drug Profile 59

FAB-001 - Drug Profile 61

FSI-1671 - Drug Profile 62

FSI-1686 - Drug Profile 63

G-3KL - Drug Profile 64

GN-4474 - Drug Profile 65

GYR-12 - Drug Profile 66

HT-06 - Drug Profile 67

HT-07 - Drug Profile 68

HT-10 - Drug Profile 69

JSM-11 - Drug Profile 70

kelokardin - Drug Profile 71

LCB-100200 - Drug Profile 72

MDN-0057 - Drug Profile 73

Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 75

NCL-195 - Drug Profile 76

NOSO-95179 - Drug Profile 77

NP-432 - Drug Profile 78

Peptides for Infectious Diseases - Drug Profile 79

pneumonia vaccine - Drug Profile 80

RXP-873 - Drug Profile 81

SLP-0901 - Drug Profile 83

SLP-0905 - Drug Profile 84

Small Molecule for Acinetobacter baumannii Infections - Drug Profile 85

Small Molecule for Bacterial Infections - Drug Profile 86

Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 87

Small Molecules for Acinetobacter baumannii Infection - Drug Profile 88

Small Molecules for Bacterial and Fungal Infections - Drug Profile 89

Small Molecules for Bacterial Infections - Drug Profile 90

Small Molecules for Bacterial Infections - Drug Profile 91

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 92

Small Molecules to Inhibit DNA Gyrase Subunit A and Topoisomerase IV for Gram-Negative Bacterial Infections - Drug Profile 93

Small Molecules to Inhibit Lipopolysaccharide for Bacterial and Nosocomial Infections - Drug Profile 94

Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 95

SPR-206 - Drug Profile 96

SPR-741 - Drug Profile 97

Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 100

Synthetic Peptides for Infectious Disease - Drug Profile 101

TN-5 - Drug Profile 102

TP-6076 - Drug Profile 103

VNRX-5113 - Drug Profile 105

VT-03 - Drug Profile 106

VXD-001 - Drug Profile 107

VXD-003 - Drug Profile 108

XEL-1001 - Drug Profile 109

XEL-1002 - Drug Profile 110

XEL-1003 - Drug Profile 111

XEL-1007 - Drug Profile 112

Acinetobacter Infections - Dormant Projects 113

Acinetobacter Infections - Product Development Milestones 115

Featured News & Press Releases 115

Appendix 131

Methodology 131

Coverage 131

Secondary Research 131

Primary Research 131

Expert Panel Validation 131

Contact Us 131

Disclaimer 132

List of Tables

List of Tables

Number of Products under Development for Acinetobacter Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Acinetobacter Infections – Pipeline by Achaogen Inc, H2 2017

Acinetobacter Infections – Pipeline by Acies Bio doo, H2 2017

Acinetobacter Infections – Pipeline by Adenium Biotech ApS, H2 2017

Acinetobacter Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2017

Acinetobacter Infections – Pipeline by Atterx Biotherapeutics Inc, H2 2017

Acinetobacter Infections – Pipeline by AvidBiotics Corp, H2 2017

Acinetobacter Infections – Pipeline by Emergent BioSolutions Inc, H2 2017

Acinetobacter Infections – Pipeline by Entasis Therapeutics Inc, H2 2017

Acinetobacter Infections – Pipeline by Evaxion Biotech ApS, H2 2017

Acinetobacter Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Acinetobacter Infections – Pipeline by FOB Synthesis Inc, H2 2017

Acinetobacter Infections – Pipeline by Hsiri Therapeutics LLC, H2 2017

Acinetobacter Infections – Pipeline by LegoChem Biosciences Inc, H2 2017

Acinetobacter Infections – Pipeline by Melinta Therapeutics Inc, H2 2017

Acinetobacter Infections – Pipeline by Nosopharm SAS, H2 2017

Acinetobacter Infections – Pipeline by Novabiotics Ltd, H2 2017

Acinetobacter Infections – Pipeline by Peptilogics Inc, H2 2017

Acinetobacter Infections – Pipeline by Pfizer Inc, H2 2017

Acinetobacter Infections – Pipeline by Redx Pharma Plc, H2 2017

Acinetobacter Infections – Pipeline by Sarepta Therapeutics Inc, H2 2017

Acinetobacter Infections – Pipeline by Sealife PHARMA GMBH, H2 2017

Acinetobacter Infections – Pipeline by Shionogi & Co Ltd, H2 2017

Acinetobacter Infections – Pipeline by Techulon Inc, H2 2017

Acinetobacter Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017

Acinetobacter Infections – Pipeline by Vaxdyn SL, H2 2017

Acinetobacter Infections – Pipeline by Xellia Pharmaceuticals ApS, H2 2017

Acinetobacter Infections – Dormant Projects, H2 2017

Acinetobacter Infections – Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Acinetobacter Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports